Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China YCT Bets Company on Botanical Flu Treatment

publication date: Mar 31, 2011
China YCT International Group has acquired L.Y. (HK) Biotech Ltd., a development stage company. China YCT said its main interest in LYHK was the latter’s patent for a botanical flu treatment. To make the acquisition, China YCT transferred 44.26 million newly created shares, representing 60% of its outstanding stock. China YCT, which does not trade actively, seems to have last traded at either $.75 or $1, giving the transaction a value of between $33 million and $44 million. More details....

Stock Symbol: (Pink Sheets: CYIG)     Share this with colleagues:  


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital